Loading...
Loading...
- Stryker Corporation SYK reported 1Q FY22 results that beat on the top and bottom line, reflecting a solid rebound in procedure volumes in March.
- SYK expects FY22 organic revenue growth in its 6-8% range. SYK called out the supply chain and inflation issues and expected EPS to come near the low-end of its $9.60-10.00 range.
- RBC Capital Market remains on the sidelines at this time and maintains a Sector Perform rating.
- SYK reported Q1 sales of $4.3 billion, +8.1% Y/Y (+9.2% organic), exceeding consensus estimates and RBC estimate of $4.2 billion.
- The beat was broad-based, with numbers coming in above expectations for all sub-segments except for other ortho and neurovascular.
- While the company did report a bounce back in surgical procedures and declining COVID-19 cases, supply chain challenges and electronic component shortages constrained sales growth.
- The impact was felt the most in SYK’s MedSurg business and Medical sub-segment.
- SYK is also seeing inflation in freight costs hitting margins. SYK expects that Q2 should look similar to Q1 in terms of supply challenges.
- While the company does not expect a full recovery in the global supply chain before 2023, it does expect to be able to procure enough to meet demand by year-end.
- Price Action: SYK shares are down 3.45% at $243.39 during the market session on the last check Friday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in